The Importance of Treatment Sequencing in Mantle Cell Lymphoma
July 16th 2024We recently spoke with Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, about his team’s interim analysis of their dose-escalation study of glofitamab against relapsed/refractory B-cell non-Hodgkin lymphoma.
Read More
Clinical Trials Won’t Cause Financial Harm for Practices in Medicare Payment Models, Study Finds
June 28th 2024Ishwaria Subbiah, MD, of SCRI Oncology Partners, discusses new findings presented at ASCO 2024. This interview will appear in the annual ASCO recap issue of Evidence-Based Oncology.
Read More
BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma
June 18th 2024The treatment regimen not only significantly improved progression-free survival (PFS) for patients with advanced stage classic Hodgkin lymphoma but was also better tolerated compared with a 20-year-old regimen being used.
Read More
Tislelizumab Plus Chemo Meaningfully Improves OS, PFS in Advanced Esophageal Cancer
June 14th 2024The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.
Read More
Link Between Skin Cancer and Immunosuppressants Needs Further Research
June 13th 2024At the 2024 American Society of Clinical Oncology annual meeting, an abstract presenting real-world data stressed the need for further research regarding the association between immunosuppressant medication and the development of skin cancer.
Read More
Camrelizumab Plus Rivoceranib Improves Survival vs Standard First-Line Care for HCC
June 5th 2024In the final overall survival analysis of the phase 3 CARES-310 trial, frontline camrelizumab plus rivoceranib continued to show clinically meaningful survival benefits vs sorafenib for hepatocellular carcinoma (HCC).
Read More
Nivolumab Fails to Benefit Esophageal Cancer Treatment in EA2174 Trial: Dr Jennifer Eads
June 4th 2024This new analysis of nivolumab presented at ASCO 2024 shows the immune checkpoint inhibitor did not convery benefit when added to a regimen of neoadjuvant carboplatin, paclitaxel, and radiation.
Read More
No CRS Seen in First 10 Patients in Teclistamab Pilot With Prophylactic Tocilizumab
June 3rd 2024Results for the first 10 patients offer promising signs for giving patients with multiple myeloma a prophylactic dose of tocilizumab before they are treated with the bispecifc antibody teclistamab.
Read More
Advancing Geriatric Oncology Care Through Telehealth and the GAIN-S Model: Dr William Dale
June 2nd 2024Within the GAIN-S model, geriatric care assessments among older patients with cancer are combined with care interventions, and it is delivered soon before patients have an intervention on their cancer therapy, says William Dale, MD, PhD, FASCO, City of Hope.
Read More
City of Hope’s Dr Tycel Phillips Discusses Promise of Glofitamab in Heavily Pretreated MCL
June 1st 2024Glofitamab is currently being investigated in a phase 1/2, multicenter, open-label, dose-escalation study as monotherapy and in combination with obinutuzumab, following 1-time fixed-dose pretreatment with obinutuzumab for B-cell non-Hodgkin lymphoma, of which mantle cell lymphoma (MCL) is a rare type.
Read More